Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells

Vaccine

Volumn 32, Issue 40, 2014, Pages 5212-5220

  Pham, Giang H ^a   Iglesias, Bibiana V ^b   Gosselin, Edmund J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Cancer; Chronic infection; Dendritic cell vaccine; Fc receptor targeted vaccine; Intranasal vaccine; Vaccine platform

Indexed keywords

ANTIGEN; DENDRITIC CELL VACCINE; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; LIVE VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL ANTIGEN; BACTERIAL VACCINE; CYTOKINE; FC RECEPTOR IIB;

ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE MARROW CELL; CELL MATURATION; CELL PROTECTION; CELL SURFACE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EX VIVO STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IN VITRO STUDY; LD 50; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; VACCINATION; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; FRANCISELLA TULARENSIS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; PROCEDURES; SECRETION (PROCESS); TULAREMIA;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CYTOKINES; DENDRITIC CELLS; FRANCISELLA TULARENSIS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IGG; TULAREMIA; VACCINATION;

EID: 84906046187     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.050     Document Type: Article

References (50)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Apostolopoulos V., Thalhammer T., Tzakos A.G., Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv 2013, 2013:869718.
3. Garcia F., Plana M., Climent N., Leon A., Gatell J.M., Gallart T. Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vac Immunother 2013, 9.
4. Boonnak K., Vogel L., Orandle M., Zimmerman D., Talor E., Subbarao K. Antigen-activated dendritic cells ameliorate influenza A infections. J Clin Invest 2013, 123:2850-2861.
5. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
6. Gil M., Bieniasz M., Wierzbicki A., Bambach B.J., Rokita H., Kozbor D. Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J Immunol 2009, 183:6808-6818.
7. Rawool D.B., Bitsaktsis C., Li Y., Gosselin D.R., Lin Y., Kurkure N.V., et al. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 2008, 180:5548-5557.
8. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Ann Rev Immunol 2000, 18:709-737.
9. Keler T., Guyre P.M., Vitale L.A., Sundarapandiyan K., van De Winkel J.G., Deo Y.M., et al. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol 2000, 165:6738-6742.
10. Heijnen I.A., van Vugt M.J., Fanger N.A., Graziano R.F., de Wit T.P., Hofhuis F.M., et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996, 97:331-338.
11. Gosselin E.J., Wardwell K., Gosselin D.R., Alter N., Fisher J.L., Guyre P.M. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol 1992, 149:3477-3481.
12. Bitsaktsis C., Iglesias B.V., Li Y., Colino J., Snapper C.M., Hollingshead S.K., et al. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcgamma receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Infect Immun 2012, 80:1166-1180.
13. Sedlik C., Orbach D., Veron P., Schweighoffer E., Colucci F., Gamberale R., et al. A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation. J Immunol 2003, 170:846-852.
14. Iglesias B.V., Bitsaktsis C., Pham G., Drake J.R., Hazlett K.R., Porter K., et al. Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen. Immunol Cell Biol 2013, 91:139-148.
15. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 2001, 51:21-42.
16. Vilekar P., Awasthi V., Lagisetty P., King C., Shankar N., Awasthi S. In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine. BMC Immunol 2010, 11:60.
17. Platt A.M., Randolph G.J. Dendritic cell migration through the lymphatic vasculature to lymph nodes. Adv Immunol 2013, 120:51-68.
18. Liu Y., Gao X., Masuda E., Redecha P.B., Blank M.C., Pricop L. Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes. J Immunol 2006, 177:8440-8447.
19. Bitsaktsis C., Rawool D.B., Li Y., Kurkure N.V., Iglesias B., Gosselin E.J. Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. J Immunol 2009, 182:4899-4909.
20. Periasamy S., Singh A., Sahay B., Rahman T., Feustel P.J., Pham G.H., et al. Development of tolerogenic dendritic cells and regulatory T cells favors exponential bacterial growth and survival during early respiratory tularemia. J Leuk Biol 2011, 90:493-507.
21. Yager E., Bitsaktsis C., Nandi B., McBride J.W., Winslow G. Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice. Infect Immun 2005, 73:8009-8016.
22. Feng H.M., Whitworth T., Olano J.P., Popov V.L., Walker D.H. Fc-dependent polyclonal antibodies and antibodies to outer membrane proteins A and B, but not to lipopolysaccharide, protect SCID mice against fatal Rickettsia conorii infection. Infect Immun 2004, 72:2222-2228.
23. Edelson B.T., Unanue E.R. Intracellular antibody neutralizes Listeria growth. Immunity 2001, 14:503-512.
24. Casadevall A. Antibody-mediated protection against intracellular pathogens. Trends Microbiol 1998, 6:102-107.
25. Klimpel G.R., Eaves-Pyles T., Moen S.T., Taormina J., Peterson J.W., Chopra A.K., et al. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 2008, 26:6874-6882.
26. Mara-Koosham G., Hutt J.A., Lyons C.R., Wu T.H. Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect Immun 2011, 79:1770-1778.
27. Elkins K.L., Cowley S.C., Bosio C.M. Innate and adaptive immunity to Francisella. Ann NY Acad Sci 2007, 1105:284-324.
28. Ryden P., Twine S., Shen H., Harris G., Chen W., Sjostedt A., et al. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria. Mol Immunol 2013, 54:58-67.
29. Lin Y., Ritchea S., Logar A., Slight S., Messmer M., Rangel-Moreno J., et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009, 31:799-810.
30. Markel G., Bar-Haim E., Zahavy E., Cohen H., Cohen O., Shafferman A., et al. The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS ONE 2010, 5:e11176.
31. Skyberg J.A., Rollins M.F., Samuel J.W., Sutherland M.D., Belisle J.T., Pascual D.W. Interleukin-17 protects against the francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain. Infect Immun 2013, 81:3099-3105.
32. Green S.J., Nacy C.A., Schreiber R.D., Granger D.L., Crawford R.M., Meltzer M.S., et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from l-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun 1993, 61:689-698.
33. Takai T., Ono M., Hikida M., Ohmori H., Ravetch J.V. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996, 379:346-349.
34. Sharp P.E., Martin-Ramirez J., Boross P., Mangsbo S.M., Reynolds J., Moss J., et al. Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone. Mol Immunol 2012, 50:49-56.
35. Williams E.L., Tutt A.L., Beers S.A., French R.R., Chan C.H., Cox K.L., et al. Immunotherapy targeting inhibitory Fcgamma receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol 2013, 191:4130-4140.
36. Smyth M.J., Kershaw M.H. Immunology. The adjuvant effects of antibodies. Science 2011, 333:944-945.
37. Kalergis A.M., Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002, 195:1653-1659.
38. Kensil C.R., Mo A.X., Truneh A. Current vaccine adjuvants: an overview of a diverse class. Front Biosci 2004, 9:2972-2988.
39. Schuurhuis D.H., Ioan-Facsinay A., Nagelkerken B., van Schip J.J., Sedlik C., Melief C.J., et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002, 168:2240-2246.
40. Lavine C.L., Clinton S.R., Angelova-Fischer I., Marion T.N., Bina X.R., Bina J.E., et al. Immunization with heat-killed Francisella tularensis LVS elicits protective antibody-mediated immunity. Eur J Immunol 2007, 37:3007-3020.
41. Dreisbach V.C., Cowley S., Elkins K.L. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun 2000, 68:1988-1996.
42. Rhinehart-Jones T.R., Fortier A.H., Elkins K.L. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun 1994, 62:3129-3137.
43. Conlan W., Shen H., Kuolee R., Zhao X., Chen W. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma-dependent mechanism. Vaccine 2005, 23:2477-2485.
44. Cowley S.C., Meierovics A.I., Frelinger J.A., Iwakura Y., Elkins K.L. Lung CD4-CD8-double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol 2010, 184:5791-5801.
45. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., Young J.W. Activating inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005, 115:2914-2923.
46. Bergtold A., Desai D.D., Gavhane A., Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005, 23:503-514.
47. Yada A., Ebihara S., Matsumura K., Endo S., Maeda T., Nakamura A., et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. Cell Immunol 2003, 225:21-32.
48. Yewdall A.W., Drutman S.B., Jinwala F., Bahjat K.S., Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE 2010, 5:e11144.
49. Ronchese F., Hermans I.F. Killing of dendritic cells: a life cut short or a purposeful death?. J Exp Med 2001, 194:F23-F26.
50. Fajardo-Moser M., Berzel S., Moll H. Mechanisms of dendritic cell-based vaccination against infection. Int J Med Microbiol 2008, 298:11-20.